Citations

Clear

4799 citation(s) found for "Yu, Jennifer".

Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials
Smith, Ashley Wilder , DiMartino, Lisa , Garcia, Sofia F. , Mitchell, Sandra A. , Ruddy, Kathryn J. , Smith, Justin D. , Cahue, September, Cella, David , Jensen, Roxanne E. , Hassett, Michael J. , Hodgdon, Christine, Richardson, Kimberly, Kroner, Barbara L, Yanez, Betina R. , Bian, Jessica , Dizon, Don S. , Hazard‐Jenkins, Hannah , Ahrens, Paige, Barrett, Fiona , Begnoche, Megan, Caron, Kimberly, Coughlin, Ava , Cronin, Christine , Dias, Samira , Farisiv, Nicolas, Flores, Anne Marie, Garcia, Martha, Kircher, Sheetal , Lancki, Nicola , Mai, Quan H, McCleary, Nadine J. , Norton, Wynne E. , O’Connor, Mary , Pachman, Deirdre R. , Pearsonil, Loretta, Podratz, Jewel, Rahman, Parvez, Redmond, Sarah , Reich, James , Schaepe, Karen , Poirier-Shelton, Tiana, Silberman, Philip , Simpson, Jaclyn, Tasker, Laura, Tesch, Nathan , Tramontano, Angela C. , Jensen, Roxanne E , Osarogiagbon, Raymond U , Cheville, Andrea L , Mitchell, Sandra A , Garcia, Sofia F , Wong, Sandra L. , Kroner, Barbara, Osarogiagbon, Raymond U. , Popovic, Jennifer R. , Schrag, Deborah , Cheville, Andrea , Kroner, Barbara L, Griffin, Joan M. , Ardini, Mary-Anne , Austin, Jessica D. , Barrett, Fiona, Bass, Michael , Chlan, Linda L. , Hemming, Karla , Herrin, Jeph , Kroenke, Kurt , Lam, Veronica, Mai, Quan H, Mallow, Jennifer A. , Penedo, Frank J. , Preiss, Liliana , Reich, James, Richardson, Joshua E. , Ridgeway, Jennifer L. , Rutten, Lila J. Finney , Scholtens, Denise M. , Tofthagen, Cindy , Tyndall, Benjamin D. , Uno, Hajime , Wehbe, Firas , Weiner, Bryan Jeffrey

Mayo Clinic

JNCI Cancer Spectrum | November 6, 2023 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/jncics/pkad073 | PMID 37930033 Get It

AbstractCancer and its treatment produce deleterious symptoms across the phases of care. Poorly controlled symptoms negatively affect quality of life and result in increased health-care needs and hospitalization. The Improving the Management of symPtoms during And following Cancer Treatment (IMPACT) Consortium was created to develop 3 large-scale, systematic symptom management systems, deployed through electronic health record platforms, and to test them in pragmatic, randomized, hybrid effectiveness and implementation trials. Here, we describe the IMPACT Consortium’s conceptual framework, its organizational components, and plans for evaluation. The study designs and lessons learned are highlighted in the context of disruptions related to the COVID-19 pandemic.
Disparities in electronic health record portal access and use among patients with cancer
Griffin, Joan M. , Kroner, Anna , Wong, Sandra L. , Cheville, Andrea , Mitchell, Sandra A. , Lancki, Nicola , Hassett, Michael J. , Schrag, Deborah , Ridgeway, Jennifer L. , Cella, David , Flores, Ann Marie , Yanez, Betina R. , Hazard‐Jenkins, Hannah , Kroner, Barbara L , Cheville, Andrea L , Mitchell, Sandra A , Lancki, Nicola , Schrag, Deborah , Osarogiagbon, Raymond U , Ridgeway, Jennifer L , Cella, David , Jensen, Roxanne E , Flores, Ann Marie , Austin, Jessica D , Yanez, Betina , Griffin, Joan M , Wong, Sandra , Preiss, Liliana , Smith, Ashley Wilder , Osarogiagbon, Raymond U. , Jensen, Roxanne E. , Austin, Jessica D.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 6, 2023 | Volume: 116 | Issue: 3 | Pages: 476-484

10.1093/jnci/djad225 | PMID 37930884 Get It

Abstract Background Electronic health record–linked portals may improve health-care quality for patients with cancer. Barriers to portal access and use undermine interventions that rely on portals to reduce cancer care disparities. This study examined portal access and persistence of portal use and associations with patient and structural factors before the implementation of 3 portal-based interventions within the Improving the Management of symPtoms during And following Cancer Treatment (IMPACT) Consortium. Methods Portal use data were extracted from electronic health records for the 12 months preceding intervention implementation. Sociodemographic factors, mode of accessing portals (web vs mobile), and number of clinical encounters before intervention implementation were also extracted. Rurality was derived using rural-urban commuting area codes. Broadband access was estimated using the 2015-2019 American Community Survey. Multiple logistic regression models tested the associations of these factors with portal access (ever accessed or never accessed) and persistence of portal use (accessed the portal ≤20 weeks vs ≥21 weeks in the 35-week study period). Results Of 28 942 eligible patients, 10 061 (35%) never accessed the portal. Male sex, membership in a racial and ethnic minority group, rural dwelling, not working, and limited broadband access were associated with lower odds of portal access. Younger age and more clinical encounters were associated with higher odds of portal access. Of those with portal access, 25% were persistent users. Using multiple modalities for portal access, being middle-aged, and having more clinical encounters were associated with persistent portal use. Conclusion Patient and structural factors affect portal access and use and may exacerbate disparities in electronic health record–based cancer symptom surveillance and management.
Hdac1 and Hdac2 positively regulate Notch1 gain‐of‐function pathogenic signaling in committed osteoblasts of male mice
Oliveira, Haydée Torres de , Hinojosa, Leetoria, VanCleave, Ashley M. , Rodezno, Tania G., Westendorf, Jennifer J., Torres, Haydee M , Westendorf, Jennifer J. , Tao, Jianning

Mayo Clinic

Birth Defects Research | November 3, 2023 | Volume: 116 | Issue: 1 | Pages: No page available

10.1002/bdr2.2266 | PMID 37921375 Get It

AbstractBackgroundSkeletal development requires precise extrinsic and intrinsic signals to regulate processes that form and maintain bone and cartilage. Notch1 is a highly conserved signaling receptor that regulates cell fate decisions by controlling the duration of transcriptional bursts. Epigenetic molecular events reversibly modify DNA and histone tails by influencing the spatial organization of chromatin and can fine‐tune the outcome of a Notch1 transcriptional response. Histone deacetylase 1 and 2 (HDAC1 and HDAC2) are chromatin modifying enzymes that mediate osteoblast differentiation. While an HDAC1‐Notch interaction has been studied in vitro and in Drosophila, its role in mammalian skeletal development and disorders is unclear. Osteosclerosis is a bone disorder with an abnormal increase in the number of osteoblasts and excessive bone formation.MethodsHere, we tested whether Hdac1/2 contribute to the pathogenesis of osteosclerosis in a murine model of the disease owing to conditionally cre‐activated expression of the Notch1 intracellular domain in immature osteoblasts.ResultsImportantly, selective homozygous deletions of Hdac1/2 in osteoblasts partially alleviate osteosclerotic phenotypes (Col2.3kb‐Cre; TGRosaN1ICD/+; Hdac1flox/flox; Hdac2flox/flox) with a 40% decrease in bone volume and a 22% decrease in trabecular thickness in 4 weeks old when compared to male mice with heterozygous deletions of Hdac1/2 (Col2.3 kb‐Cre; TGRosaN1ICD/+; Hdac1flox/+; Hdac2flox/+). Osteoblast‐specific deletion of Hdac1/2 in male and female mice results in no overt bone phenotype in the absence of the Notch1 gain‐of‐function (GOF) allele.ConclusionsThese results provide evidence that Hdac1/2 contribute to Notch1 pathogenic signaling in the mammalian skeleton. Our study on epigenetic regulation of Notch1 GOF‐induced osteosclerosis may facilitate further mechanistic studies of skeletal birth defects caused by Notch‐related GOF mutations in human patients, such as Adams‐Oliver disease, congenital heart disease, and lateral meningocele syndrome.
Wireless Stimulation of Motor Cortex Through a Collagen Dura Substitute Using an Ultra-Thin Implant Fabricated on Parylene/PDMS
Benbuk, Ahmed Abed , Liu, Shiyi , Quiñones‐Hinojosa, Alfredo , Christen, Jennifer Blain , Benbuk, Abed , Blain Christen, Jennifer , Gulick, Daniel , Moniz‐Garcia, Diogo

Mayo Clinic

IEEE Transactions on Biomedical Circuits and Systems | November 1, 2023 | Volume: 18 | Issue: 2 | Pages: 334-346

10.1109/tbcas.2023.3329447 | PMID 37910421 Get It

Lower academic performance among children with perinatal HIV exposure in Botswana
Powis, Kathleen M. , Lebanna, Lesedi, Masasa, Gosego, Kgole, Samuel W. , Ngwaca, Martha, Kgathi, Coulson, Slogrove, Amy L. , Shapiro, Roger , Lockman, Shahin , Mmalane, Mompati, Makhema, Joseph , Jao, Jennifer , Cassidy, Adam R. , Slogrove, Amy L , Lebanna, Lesedi, Schenkel, Sara Rae , Ngwaca, Martha, Williams, Paige L.

Mayo Clinic

Journal of the International AIDS Society | November 1, 2023 | Volume: 26 | Issue: S4 | Pages: No page available

10.1002/jia2.26165 | PMID 37909233 Get It

AbstractIntroductionStudies have reported a higher risk of suboptimal neurodevelopment among children who are HIV‐exposed uninfected (HEU) compared to children HIV‐unexposed uninfected (HUU). Actual academic performance among school‐aged children by HIV exposure status has not been studied.MethodsAcademic performance in Mathematics, Science, English, Setswana and overall among children enrolled in the Botswana‐based FLOURISH study who were attending public primary school and ranging in age from 7.1 to 14.6 years were compared by HIV exposure status using a Cochran‐Mantel‐Haenszel test. Lower academic performance was defined as a grade of “C” or lower (≤60%). Unadjusted and adjusted logistic regression models were fit to assess for an association between HIV exposure and lower academic performance.ResultsBetween April 2021 and December 2022, 398 children attending public primary school enrolled in the FLOURSH study, 307 (77%) were HEU. Median age was 9.4 years (IQR 8.9–10.2). Only 17.9% of children HEU were breastfeed versus 100% of children HUU. Among children HEU, 80.3% had foetal exposure to three‐drug antiretroviral treatment, 18.7% to zidovudine only and 1.0% had no antiretroviral exposure. Caregivers of children HEU were older compared to caregivers of children HUU (median 42 vs. 36 years) and more likely to have no or primary education only (15.0% vs. 1.1%). In unadjusted analyses, children HEU were more likely to have lower overall academic performance compared to their children HUU (odds ratio [OR]: 1.96 [95% confidence interval (CI): 1.16, 3.30]), and lower performance in Mathematics, Science and English. The association was attenuated after adjustment for maternal education, caregiver income, breastfeeding, low birth weight and child sex (aOR: 1.86 [95% CI: 0.78, 4.43]).ConclusionsIn this Botswana‐based cohort, primary school academic performance was lower among children HEU compared to children HUU. Biological and socio‐demographic factors, including child sex, appear to contribute to this difference. Further research is needed to identify modifiable contributors, develop screening tools to identify the risk of poor academic performance and design interventions to mitigate risk.
Selecting an Alternative Contrast Agent to Prevent Repeat Allergic-like Reactions
McDonald, Jennifer S.

Mayo Clinic

Radiology | October 31, 2023 | Volume: 309 | Issue: 1 | Pages: No page available

10.1148/radiol.231979 | PMID 37906007 Get It

754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)
Chumsri, Saranya , Migdady, Yazan , Chaudhary, Lubna N. , Kim, Chul , Fitzsimmons, Sarah, Ganguly, Bishwa J, Hiraragi, Hajime, Jensen, H.R., Kim, Yeonhee , Lessig, Mary, Gillenwater, Heidi H., Spigel, David R. , Hamilton, Erika , Bashir, Babar , Gergis, Usama , Murthy, Hemant S. , Specht, Jennifer M. , Garber, Haven R. , Mamdani, Hirva Mansurali , Jensen, Helle

Mayo Clinic

Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A850-A850

10.1136/jitc-2023-sitc2023.0754 Get It

750 A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers
Uboha, Nataliya V. , Chaves, Jorge, Powderly, John D. , Gabrail, Nashat , Zhaohui, Jin, Alistar, Angela , Agensky, Laura, Goel, Apollina, Margossian, Steven, Quayle, Steve, Levisetti, Matteo, Selfridge, Jennifer Eva , Saenger, Yvonne M. , Zheng, Lei , Kim, Dae Won , Alese, Olatunji B. , Fu, Siqing , Gong, Jun , Zhaohui, Jin, Bekaii‐Saab, Tanios

Mayo Clinic

Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A846-A846

10.1136/jitc-2023-sitc2023.0750 Get It

636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials
Hecht, J. Randolph, Smith, Caleb J. , Welling, Theodore H., Morelli, Maria Pia , Grierson, Patrick , Vu, Peter , Dahiya, Saurabh , Jacobson, Caron A. , Lozac’hmeur, Ariane, Tebbets, Jessica , Ong, Gayanie, Go, William Y., Welch, John S. , Maloney, David G. , Molina, Julian R. , Simeone, Diane M. , Fakih, Marwan , Garon, Edward B. , Kirtane, Kedar , Locke, Frederick L. , Dorigo, Oliver , Park, Jong Chul , Specht, Jennifer M. , Dragovich, Tomislav , Ng, Eric W, Maus, Marcela V

Mayo Clinic

Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A727-A728

10.1136/jitc-2023-sitc2023.0636 Get It